Key clinical point: Combination gemcitabine, rituximab, and oxaliplatin, followed by lenalidomide maintenance appeared safe and effective as salvage therapy for patients with relapsed/refractory non-Hodgkin lymphoma (NHL).
Major finding: Among all evaluable patients, the overall response rate was 61% and 2-year overall survival of 47%.
Study details: A phase 2 pilot study of 33 patients with relapsed/refractory NHL, including 28 patients with diffuse large B-cell lymphoma.
Disclosures: The study was funded by Celgene. The authors reported financial affiliations with Astra Zeneca, Biodesix, Bristol-Myers Squibb, Celgene, Eli Lilly, Merck, and Seattle Genetics.
Cabanillas F et al. Clin Lymphoma Myeloma Leuk. 2019 Jul 17. doi: 10.1016/j.clml.2019.07.002.